Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth - Quiz - MDSpire

Evaluating Treatment Outcomes of Venetoclax Combined with Azacitidine in High-Risk Myelodysplastic Syndromes: A Framework for Understanding Response Depth

By
Xinfu Zou
Jinyang Bu
Aojiao Chu
Ling Shi
Zheng Zhang
Qin Zheng
Meihong Luo
August 24, 2026

Frontiers In Medicine

Share

Original Source(s)

Frontiers In Medicine

Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth

by Xinfu Zou, Jinyang Bu, Aojiao Chu, Ling Shi, Zheng Zhang, Qin Zheng, Meihong Luo
August 24, 2026

Related Content

Updates In Surgery

Transitioning from hand-sewn to circular stapled cervical anastomosis after minimally invasive esophagectomy: a Western centre propensity score matching analysis

Hemasphere

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial

Frontiers In Oncology

Commentary: Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins

by Mengjie Xue, Jihong Peng
August 24, 2026